4+ hour, 42+ min ago  (805+ words) The Clinical Trial Vanguard What the MASAI Trial Correspondence in The Lancet Actually Says About AI Screening Evidence On June 28, 2026, The Lancet published a correspondence letter responding to the MASAI trial's conclusions on AI-supported mammography screening. The letter deserves careful…...

3+ week, 4+ day ago  (425+ words) The Clinical Trial Vanguard FDA Accepts NDA for Roche's Giredestrant in Early-Stage Breast Cancer A 30% reduction in invasive disease recurrence or death " hazard ratio 0. 70, p=0. 0014 " is the number that earned giredestrant priority review, and it reframes what adjuvant endocrine therapy…...